Basal Instincts: Towards Better Understanding of Basal Cell Function in Chronic Rhinosinusitis With Nasal Polyps

Sponsor
Universitaire Ziekenhuizen KU Leuven (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06129552
Collaborator
Regeneron Pharmaceuticals (Industry)
300
49

Study Details

Study Description

Brief Summary

During this project, the investigators want to explore in vitro changes in basal cells and the crosstalk with residing immune cells as potential pathogenic mechanisms in CRSwNP vs healthy controls by using surgically resected patient samples.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation

Detailed Description

The investigators want to use patient and healthy control samples to study/compare the following aspects in vitro:

  1. Investigate differences in epithelial and basal cell functions and differentiation characteristics.

  2. Characterize the differences in epithelial cell populations and gene expression patterns. Also include an AR subset, to see if changes are specific for CRSwNP or more general for type 2 inflammatory disease of the upper airways.

  3. Investigate basal cell activation via different environmental triggers through TLR stimulation.

  4. Look at the genetic imprinting of basal cells before and after being exposed to specific triggers.

  5. Investigate whether the secreted proteins from basal cells are chemotactic for other cell populations.

  6. Investigate the interaction between basal and regulatory T cells.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Basal Instincts: Towards Better Understanding of Basal Cell Function in Chronic Rhinosinusitis With Nasal Polyps
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2027
Anticipated Study Completion Date :
Dec 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Healthy controls

Procedure: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.

CRSwNP patients

Procedure: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.

AR patients

Procedure: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.

Outcome Measures

Primary Outcome Measures

  1. Functional differences between epithelial/basal cells from CRSwNP samples in comparison to healthy controls assessed with functional assays. [12-24 months]

    Multiple techniques and functional assays will be used to fully investigate the functional differences between epithelial/basal cells isolated from healthy and CRSwNP samples. The differences in barrier composition will be assessed through TEER measurements (Ω × cm2) and FD4 permeability assays (ng/ml). Moreover, barrier composition is investigated by examining differences in membrane markers and junction expression through immunofluorescence and RT-qPCR. Finally, primary isolated cells will be used to assess protein levels through immunostainings, flow cytometry, and Western blots.

  2. Characterization of differences in gene expression profiles and epithelial populations in/between CRSwNP and healthy controls assessed with different sequencing techniques. [9-18 months]

    To characterize differences in gene expression, or identify specific genes/cell populations that can contribute to CRSwNP, scRNA-sequencing will be performed, as well as bulk RNA sequencing. Depending on these results, specific triggers or receptors that can contribute to CRSwNP will be investigated by stimulation experiments. Besides, the effect on epigenetic imprinting before and after stimulation by performing ATAC-sequencing or DNA methylation profiling will be studied as well.

  3. Changes and interactions in the basal and regulatory T-cell axis between healthy and CRSwNP-isolated cells will be studied through co-culture experiments. [9-18 months]

    The interaction between basal and regulatory T cells in relation to homeostasis and regeneration, and how this might change or contribute in/to CRSwNP will be investigated by co-culturing these cells. This will be assessed through the analysis of the supernatants using the Olink platform to investigate cytokines etc. Besides, there will be bulk RNA sequencing to look at changes in gene expression, as well as proliferation and growth assays to see the effect of T cells on basal cells and vice versa. To look at functional changes we can asses different functional assays and techniques (see outcome 1).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients over the age of 18

  • Males and females

Exclusion Criteria:
  • CRSwNP

  • AR

  • Smoker, or < 1-year ex-smoker

  • Underlying systematic pathology (Morbus Wegener or Churg Strauss Syndrome for example)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Universitaire Ziekenhuizen KU Leuven
  • Regeneron Pharmaceuticals

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Universitaire Ziekenhuizen KU Leuven
ClinicalTrials.gov Identifier:
NCT06129552
Other Study ID Numbers:
  • S67788
First Posted:
Nov 13, 2023
Last Update Posted:
Nov 13, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 13, 2023